Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779411 | 0.90 | CCR2 (0.70) | CCR2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL1778747 | 0.90 | CCR2 (0.67) | CCR2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL1780983 | 0.85 | CCR2 (0.54) | CCR2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL1779370 | 0.85 | CCR2 (0.52) | CCR2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL3233950 | 0.82 | CCR2 (0.82) | CCR2 | |
| SCHEMBL1780050 | 0.80 | CCR2 (0.48) | CCR2OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL1780892 | 0.73 | CCR2 (1.00) | CCR2 | |
| SCHEMBL1780135 | 0.72 | CCR2 (1.00) | CCR2 | |
| SCHEMBL1782801 | 0.70 | CCR2 (0.62) | CCR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14237076 | 0.69 | CCR2 (1.00) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| EP-2318352-A2 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118354-A1 | CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | CCR2 2/4885OPRM1 194/4885OPRL1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.